Clinical Trials

28 enrolled

LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes, Neoplasms

NCT02783625 2026-04-24

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

114 enrolled

Lymphoma, Lymphoma, T-Cell

NCT04996160 2026-04-17

Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

2 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

50 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02312102 2026-01-16

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

MyeloidOther hematologic neoplasm

22 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03828292 2025-08-19

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

15 enrolled 91 charts

Multiple Myeloma

NCT00329589 2025-05-02

A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

CNSGynecologicHead & Neck

54 enrolled

Brain Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Central Nervous System Neoplasms

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

240 enrolled 1 FDA

Multiple Myeloma

NCT01163357 2025-03-26

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Other hematologic neoplasmPlasma cell

Chromosome 17 deletion, Leukemia, Plasma Cell, Multiple Myeloma

NCT03829020 2024-08-22

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

9 enrolled

Multiple Myeloma

NCT02513186 2024-01-29

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

90 enrolled

Multiple Myeloma

NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasmPlasma cell

15 enrolled

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02514382 2023-08-14

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

14 enrolled

Multiple Myeloma

NCT00664898 2022-12-12

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02613598 2021-12-20

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

15 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT01038388 2021-11-03

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

30 enrolled

Multiple Myeloma

NCT03056599 2021-09-24

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

23 enrolled

Sarcoma

NCT01965353 2021-09-05

PanRVD

21 enrolled

Multiple Myeloma

NCT02481934 2021-08-20

NK-VS-MM

5 enrolled 6 charts

Multiple Myeloma

NCT01794507 2021-08-02

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

66 enrolled

Multiple Myeloma

NCT00858234 2021-04-09

MK-0683-098

9 enrolled 9 charts

Multiple Myeloma

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

241 enrolled 31 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02100657 2020-10-12

Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

39 enrolled 30 charts

Multiple Myeloma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Other hematologic neoplasmPlasma cell

55 enrolled

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT00598169 2020-08-10

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

23 enrolled

Lymphoma

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

34 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00568880 2020-02-07

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

25 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01464112 2020-01-22

A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma

Multiple Myeloma

NCT01445405 2019-12-17

Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer

3 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Pharyngeal Neoplasms

NCT00023855 2019-12-13

PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00011778 2019-12-12

PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck

25 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT01074411 2019-08-09

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

33 enrolled

Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01164709 2019-05-15

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Congenital Abnormalities, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell

NCT02497378 2019-03-07

A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

8 enrolled

Multiple Myeloma

NCT01440582 2019-03-04

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

77 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00059631 2018-11-15

Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone

42 enrolled

Genitourinary

Prostatic Neoplasms

NCT00777114 2018-08-13

Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy

31 enrolled

Lymphoma, Non-Hodgkin

NCT01428492 2018-08-08

PKB115125

Other hematologic neoplasmPlasma cell

90 enrolled

Multiple Myeloma, Hematologic Neoplasms

NCT01936090 2018-05-24

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

11 enrolled

Multiple Myeloma

NCT01711528 2018-05-11

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

41 enrolled

Multiple Myeloma

NCT00963274 2018-04-23

Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell

NCT00290680 2018-04-10

Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors

36 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT01016730 2018-02-20

Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

24 enrolled

Sarcoma

AIDS-related Kaposi sarcoma, Sarcoma, Kaposi, HIV Infections

NCT02220608 2018-01-08

Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma

10 enrolled

Multiple Myeloma

NCT00622674 2017-12-02

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

37 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT00620295 2017-11-29

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

17 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Uterine Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT00624936 2017-08-22

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

MyeloidOther hematologic neoplasm

23 enrolled

Congenital Abnormalities, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT00541359 2017-08-09

Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

54 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00644696 2017-07-06

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma